title: Technology evaluation: mepolizumab, GlaxoSmithKline.
abstract: GlaxoSmithKline (formerly SmithKline Beecham) is developing mepolizumab (SB-240563), a monoclonal antibody directed against IL-5, as a potential treatment for asthma and atopic dermatitis. Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis.
authors.affiliation: Mail Point 810, Level D, Centre Block, Southampton General Hospital, Southampton, SO16 6YD, UK.
authors.forename: Gnanasegaram
authors.initials: G
authors.lastname: Gnanakumaran
authors.forename: K Suresh
authors.initials: KS
authors.lastname: Babu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C434107:mepolizumab